Emerald Mutual Fund Advisers Trust Akero Therapeutics, Inc. Transaction History
Emerald Mutual Fund Advisers Trust
- $1.47 Billion
- Q2 2025
A detailed history of Emerald Mutual Fund Advisers Trust transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Emerald Mutual Fund Advisers Trust holds 136,297 shares of AKRO stock, worth $6.34 Million. This represents 0.49% of its overall portfolio holdings.
Number of Shares
136,297
Previous 207,035
34.17%
Holding current value
$6.34 Million
Previous $8.38 Million
13.22%
% of portfolio
0.49%
Previous 0.68%
Shares
6 transactions
Others Institutions Holding AKRO
# of Institutions
297Shares Held
92.2MCall Options Held
1.72MPut Options Held
901K-
Janus Henderson Group PLC London, X06.74MShares$314 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$267 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$260 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$255 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$211 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.16B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...